截至2026年1月9日 13:15，创新药ETF天弘(517380)盘中换手2.54%，成交4041.23万元。跟踪的恒生沪深港创新药精选50指数 (HSSSHID)一度跌超1.5%，随后反转拉升翻红。成分股药明合联(02268)上涨3.14%，迪哲医药(688192)上涨2.92%，皓元医药 (688131)上涨2.48%，绿叶制药(02186)上涨2.03%，美迪西(688202)上涨1.89%。 拉长时间看，截至1月8日，创新药ETF天弘(517380)最新规模达15.97亿元，最新份额达19.80亿份，创成立以来新高。 从资金净流入方面来看，创新药ETF天弘(517380)近3天获得连续资金净流入，最高单日获得8941.75万元净流入，合计"吸 金"1.15亿元。 【产品亮点】 创新药ETF天弘(517380)，对应场外联接基金(A类：014564；C类：014565)。 【机构观点】 万联证券指出，2025年FDA批准新药的创新"质量"提升和技术平台多元化，国内药企崭露头角。建议聚焦前沿技术平台，重点 关注拥有ADC、siRNA、细胞基因治疗（CGT）等前沿技术平台的公司；建议布局具有"出海"潜力的 ...

Core Viewpoint - The innovative drug ETF Tianhong (517380) has seen significant trading activity and growth, indicating a strong interest in the innovative drug sector, which is experiencing a historic surge in IPOs and commercialization efforts [1][4]. Group 1: ETF Performance - As of January 8, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 18.58 million yuan, with the tracked index HSSSHID rising by 0.92% [1]. - The latest scale of the innovative drug ETF Tianhong reached 1.578 billion yuan, with a total of 1.962 billion shares, both marking all-time highs since its inception [2]. - The net inflow of funds into the innovative drug ETF Tianhong was 89.42 million yuan, the highest since April 2025 [3]. Group 2: Market Trends - The innovative drug sector is experiencing a "volume and price increase" opportunity, with the top ten constituent stocks of the ETF heavily weighted towards leading companies like WuXi AppTec and HengRui Medicine, benefiting from a surge in business development (BD) transactions and breakthroughs in AI drug development [3]. - In 2025, the innovative drug sector achieved a historic explosion, with over 30 biotech companies successfully listed in A-shares and Hong Kong, and more than 50 companies awaiting approval, reflecting unprecedented capital activity [4]. - The sector has transitioned from mere speculation to substantial commercialization, becoming a benchmark sector with both growth potential and certainty in the current bull market [4]. Group 3: Institutional Insights - Southwest Securities noted that in early 2025, Hong Kong companies began achieving BD, leading to a rise in the innovative drug sector; a government report in March emphasized support for innovative drugs and medical devices, further boosting A-share performance [5]. - The sector experienced a significant price increase following a major BD deal worth 1.25 billion USD in May, but faced a high-level adjustment by the end of the third quarter [5]. - The firm predicts that in 2026, the innovative drug sector will shift from a broad rally to a selective stock market [5].

拉长时间看，截至1月6日，创业板ETF天弘(159977)近2周规模增长4.19亿元，近2周份额增长1.06亿份，实现显著增长。 资金流入方面，创业板ETF天弘(159977)近5个交易日合计"吸金"近2亿元。 截至2026年1月7日 14:15，创业板ETF天弘(159977)成交1.64亿元。跟踪的创业板指数(399006)上涨0.21%，成分股南大光电 (300346)上涨19.57%，中伟股份(300919)上涨11.83%，鼎龙股份(300054)上涨11.57%，珂玛科技(301611)上涨9.09%，大族数控 (301200)上涨7.06%。 【机构观点】 东方财富证券指出，春季躁动"抢跑"意味着行情的启动时点前移至上一年的11月或12月，近期春季行情的"抢跑"本质是在政策 预期乐观且景气主线明朗的背景下，由增量资金推动的一次估值上修。 政策预期方面，市场期待较高的中央经济工作会议延续积极定调；宏观流动性层面，全球与国内流动性环境宽松共振；景气线 索方面，市场呈现出科技成长与周期修复多线并进的结构。 资金面，机构和杠杆资金的边际增量入场迹象明显，居民存款搬家可能是重要增量，ETF成为本轮行情重要 ...

截至2026年1月7日 10:57，创新药ETF天弘(517380)成交2836.08万元。跟踪的恒生沪深港创新药精选50指数(HSSSHID)强势拉升 涨近3%，冲击四连阳！成分股凯莱英(06821)上涨7.30%，益方生物(688382)上涨6.83%，昭衍新药(603127)上涨6.66%，美迪西 (688202)，昭衍新药(06127)等个股跟涨。 【产品亮点】 创新药ETF天弘(517380)横跨沪港深三地市场，精选50只头部创新药企业，4成港股搭配6成A股，全面覆盖生物制品、化学制药 等核心领域，实现跨市场布局。 创新药ETF天弘(517380)，对应场外联接基金(A类：014564；C类：014565)。 【热点事件】 医保商保目录同步落地，创新药国产占比超8成迎放量 2026年1月1日，新版国家医保目录与首版商业保险创新药目录同步实施，新增50种一类创新药及19种商保目录药品，构建"医保 +商保"支付闭环。2025年我国批准76个创新药，较2024年的48个大幅增长58.3%，创下新的年度纪录，其中国产占比超80%，为 2026年销售放量奠定基础。 中泰证券认为，创新驱动、产业升级引领下的医药 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the Tianhong Chemical ETF (159133), which saw a turnover of 4.42% and a transaction volume of 26.6075 million yuan, with the underlying index rising by 1.84% to reach a new annual high [1][3] - The Tianhong Chemical ETF has achieved a record high in size at 629 million yuan and a record high in shares at 567 million, with a net inflow of 21.9844 million yuan recently [3] - The chemical sector is characterized by its complexity and rapid rotation, with the Tianhong Chemical ETF tracking 50 leading companies, covering both traditional cyclical sectors and emerging growth areas [3] Group 2 - Recent news indicates that major companies in the lithium iron phosphate industry, including Wanrun New Energy and Hunan Youneng, have announced maintenance and production cuts, with reductions of 35% to 50% planned for January 2026 [3][4] - Research institutions suggest that the collective maintenance in the lithium iron phosphate industry is a response to rising raw material costs, leading to increased operational pressure on companies [4] - The lithium battery supply chain is experiencing a rise in both volume and price, with significant increases in production and prices for lithium carbonate and lithium iron phosphate, indicating a recovery in downstream demand [5]

Group 1 - The core viewpoint of the news highlights the significant growth in the Securities ETF (159841), with a turnover of 5.38% and a transaction volume of 578 million yuan as of December 5, 2025, alongside a strong performance of the underlying index, which rose by 2.54% [1] - The Securities ETF has seen a notable increase in scale, growing by 19.2 million yuan over the past two weeks and 514 million shares in the last month, reaching a total of 9.999 billion shares [1] - In terms of capital inflow, the Securities ETF attracted a total of 562 million yuan over the last 20 trading days, indicating strong investor interest [2] Group 2 - The Securities sector is characterized by a strong beta attribute, closely linked to the performance of the capital market, and is often referred to as the "flag bearer of bull markets" [3] - A recent notification from the National Financial Regulatory Administration aims to enhance the role of insurance funds as "patient capital," which is expected to further open up space for insurance capital in the market [4] - The notification includes adjustments to risk factors for insurance companies, such as reducing the risk factor for stocks held over three years from 0.3 to 0.27, which is anticipated to encourage long-term investments and positively impact the capital market [5][7] Group 3 - According to Zhongyuan Securities, the overall performance of the equity market is expected to remain relatively strong in 2026, with the securities industry continuing to be in an upward cycle [8] - It is anticipated that the brokerage sector will experience wide fluctuations in 2026, with leading listed brokerages likely to play a pivotal role during the next market rally [8]

Core Insights - The chemical ETF Tianhong (159133) has seen significant trading activity, with a transaction volume of 9.8014 million yuan and a strong increase of 1.26% in the underlying index as of November 27, 2025 [1] - The ETF has attracted over 8.8 million yuan in net inflows since its listing, reaching a record high of 558 million shares [1] - The launch of China's first green hydrogen coal chemical project marks a significant step towards the green transformation of the coal chemical industry [1] Product Highlights - The Tianhong chemical ETF (159133) tracks the CSI sub-sector chemical industry theme index, which includes companies involved in chemical products, fibers, fertilizers, and pesticides, providing a representative tool for investors [1] Key Events - The successful market operation of the first green hydrogen coupling coal chemical demonstration project in China demonstrates a replicable model for the green transformation of the coal chemical industry [1] - The project has achieved breakthroughs in core technologies, including the establishment of a large-capacity electrolyzer for stable operation in the chemical industry [2] Institutional Perspectives - Western Securities notes that the chemical industry is currently experiencing a dual bottom in valuation and profitability, with a 7.45% year-on-year increase in net profit for the basic chemical sector from Q1 to Q3 of 2025 [2] - The report highlights the importance of addressing internal competition within various sub-industries and anticipates an upward trend in the economic cycle due to resource supply constraints and steady demand recovery [2]

Group 1 - The aerospace ETF Tianhong (159241) has seen a trading volume of 3.69% and a transaction value of 19.1774 million yuan, while the CN5082 index tracking the aerospace industry has decreased by 0.14% [1] - The ETF has experienced a significant growth of 17.6 million yuan in scale over the past six months, with a recent net inflow of 4.5565 million yuan [1] - The Tianhong aerospace ETF is highly concentrated in military attributes, with 97.86% of its holdings in the military industry, and a substantial 66.8% weight in aerospace equipment [1] Group 2 - The National Space Administration has issued a plan with 22 key measures to promote high-quality and safe development of the commercial aerospace sector from 2025 to 2027 [2] - The action plan aims for a significantly expanded commercial aerospace industry by 2027, with improved resource utilization and enhanced governance capabilities [2] Group 3 - The 2025 Asian General Aviation Exhibition is being held in Zhuhai from November 27 to November 30, featuring a theme focused on low-altitude economic opportunities [3] - The exhibition has doubled in size to 60,000 square meters, attracting nearly 400 companies from 22 countries and regions, showcasing over 170 aircraft [3] Group 4 - Tianhong Fund is hosting a live event titled "Exploring Infinite Possibilities in Low Altitude, Seizing New Trends in Military Investment" during the Asian General Aviation Exhibition [4] Group 5 - The Ministry of Transport has released typical case studies for low-altitude transportation applications, indicating a shift towards commercial applications in the low-altitude economy [5] - As operational regulations improve and pilot scenarios are implemented, the low-altitude economy is transitioning from policy-driven to commercial application [5]

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 34.38 million yuan and a strong index performance, reflecting a 3.66% increase in the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index [1] - The introduction of a commercial insurance innovative drug directory marks a significant step in China's multi-tiered medical security system, aimed at improving the accessibility and affordability of high-priced innovative drugs [2] - BeiGene reported a turnaround in profitability for the third quarter of 2025, achieving a net profit of 689 million yuan, driven by strong sales of its flagship product, Zanubrutinib [2] - Citic Securities anticipates a stable growth trend in the pharmaceutical industry, supported by policy initiatives and a return to a market pricing system based on clinical value and demand [3] Group 1: ETF Performance - The innovative drug ETF Tianhong (517380) reached a new high in scale at 1.398 billion yuan as of November 12, with a net inflow of 83.52 million yuan over the past ten trading days [1] - The ETF covers the entire industry chain from preclinical research to commercialization, capturing opportunities in the innovative drug sector [1] Group 2: Policy Developments - The recent conclusion of the national medical insurance negotiations and the introduction of a commercial insurance innovative drug directory are expected to enhance the market for high-value innovative drugs [2] - The new directory will focus on rare disease medications and unique innovative drugs, potentially breaking existing sales bottlenecks [2] Group 3: Company Performance - BeiGene's third-quarter revenue reached 10.077 billion yuan, a year-on-year increase of 41.1%, with a total revenue of 27.595 billion yuan for the first three quarters, reflecting a 44.2% growth [2] - The global sales of Zanubrutinib amounted to 7.423 billion yuan in the third quarter, with the U.S. market contributing 5.266 billion yuan, highlighting strong demand in the hematologic oncology sector [2] Group 4: Market Outlook - The pharmaceutical industry is expected to benefit from a stable and continuous growth trend, driven by supportive policies and a focus on clinical value [3]

【产品亮点】 创新药成果密集落地，生物医药景气上行，生物医药ETF(159859)布局龙头。 截至2025年11月7日 10:37，创新药ETF天弘(517380)成交776.27万元。跟踪指数成分股方面涨跌互现，新和成(002001)领涨3.80%，百济神州(06160)上涨 2.86%，百济神州(688235)上涨2.32%。 截至11月6日，创新药ETF天弘(517380)最新份额达17.40亿份，创成立以来新高。 从资金净流入方面来看，创新药ETF天弘(517380)近6天获得连续资金净流入，最高单日获得2281.80万元净流入，合计"吸金"7879.72万元。 生物医药ETF(159859)成交5304.21万元，跟踪指数成分股方面涨跌互现，华兰疫苗(301207)领涨4.16%，安科生物(300009)上涨2.53%，智飞生物(300122)上涨 1.44%。 截至11月6日，生物医药ETF(159859)近半年累计上涨20.23%，涨幅排名可比基金第一。生物医药ETF(159859)最新规模达32.66亿元，创近1月新高。生物医 药ETF(159859)最新份额达78.59亿份，创近3月新高。 ...